Phase 2 Relapsed refractory myeloma Clinical Trials
5 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–5 of 5 trials
Recruiting
Phase 1Phase 2
Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
Relapsed refractory myeloma
M.D. Anderson Cancer Center44 enrolled1 locationNCT06066359
Not Yet Recruiting
Phase 2
Place-of-care manufactured anti-BCMA chimeric antigen receptor (CAR) T-cells (ARI0002h) in patients with relapsed/refractory multiple myeloma.
Relapsed refractory myelomaMultiple Myeloma
Cell and Tissue Therapies WA, Royal Perth Hospital, East Metropolitan Health Service15 enrolled1 locationACTRN12625001031459
Recruiting
Phase 2
A Centralized Platform study for Functional High Risk Multiple Myeloma: Domain 1
Relapsed refractory myelomaMyeloma
Australasian Myeloma Research Consortium20 enrolled10 locationsACTRN12625000438459
Recruiting
Phase 2
A Centralized Platform study for Functional High Risk Multiple Myeloma - Master Protocol
Relapsed refractory myelomaMyeloma
Australasian Myeloma Research Consortium120 enrolled8 locationsACTRN12625000429459
Not Yet Recruiting
Phase 2
A phase 2 study of the feasibility and efficacy of at home patient administered subcutaneous daratumumab in patients with relapsed multiple myeloma (Dara@Home)
Relapsed refractory myelomaMyeloma
Australasian Myeloma Research Consortium50 enrolled1 locationACTRN12624001468516